For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | - | 0 | - | - |
| Research and development | 377,789 | 325,623 | 236,058 | 561,576.5 |
| General and administrative | 363,426 | 370,150 | 438,493 | 567,956.5 |
| Total expenses | 741,215 | 695,773 | 674,551 | 1,129,533 |
| Loss from operations | -741,215 | -695,773 | -674,551 | -1,129,533 |
| Interest income | 29,031 | 35,831 | 41,705 | 76,256 |
| Net loss | -712,184 | -659,942 | -632,846 | -1,053,277 |
| Basic net loss per share | 0 | 0 | 0 | -0.01 |
| Diluted net loss per share | 0 | 0 | 0 | -0.01 |
| Weighted average common stock shares outstanding - basic | 172,573,545 | 172,573,545 | 172,323,545 | -86,192,100.5 |
| Weighted average common stock shares outstanding - diluted | 172,573,545 | 172,573,545 | 172,323,545 | -86,192,100.5 |
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)